Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
VBI Vaccines doses 1st patient in 2nd study of HBV, amid Brii Bio collaboration » 08:33
01/05/22
01/05
08:33
01/05/22
08:33
VBIV

VBI Vaccines

$2.34 /

-0.13 (-5.27%)

VBI Vaccines announced…

VBI Vaccines announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 , an immunotherapeutic candidate targeting chronic hepatitis B virus, HBV. This newly announced Phase 2 study will assess VBI-2601 as an add-on therapy to the standard-of-care, nucleos, tide, reverse transcriptase inhibitor and pegylated interferon therapy, which currently has a functional cure rate of approximately 9%1. A functional cure for chronic HBV infection is defined as achievement of undetectable HBV surface antigen levels and sustained suppression of HBV DNA. As previously announced in April 2021, VBI-2601 is also being assessed in an additional Phase 2 study as part of a combination regimen with BRII-835 , an investigational small interfering ribonucleic acid targeting HBV. "Our commitment to the fight against hepatitis B includes a focus on both prevention and treatment of the disease," said Jeff Baxter, VBI's President and CEO. "More than 290 million people are chronically infected with HBV worldwide and, together with our partners, we are working hard to provide more patients with improved therapeutic options. This effort includes the assessment of new investigational treatment regimens, as in the ongoing combination study of VBI-2601 and an siRNA candidate, as well as ways to potentially improve upon functional cure rates achieved with the current standard of care, as with this newly announced Phase 2 study. We believe a multi-pronged approach is critical for driving innovation in the treatment of chronic HBV, and we look forward to sharing data from these two Phase 2 studies in the second half of 2022 and the first half of 2023, respectively." Brii Biosciences is the sponsor of this newly announced Phase 2a/2b study and, with the support of VBI, has led the design and implementation of this study as well as the ongoing Phase 2 combination study.

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

12/29/21 Jefferies
VBI Vaccines assumed with a Buy at Jefferies
02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

Hot Stocks
VBI Vaccines doses 1st patient in 2nd study of HBV, amid Brii Bio collaboration » 08:33
01/05/22
01/05
08:33
01/05/22
08:33
VBIV

VBI Vaccines

$2.34 /

-0.13 (-5.27%)

VBI Vaccines announced…

VBI Vaccines announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 , an immunotherapeutic candidate targeting chronic hepatitis B virus, HBV. This newly announced Phase 2 study will assess VBI-2601 as an add-on therapy to the standard-of-care, nucleos, tide, reverse transcriptase inhibitor and pegylated interferon therapy, which currently has a functional cure rate of approximately 9%1. A functional cure for chronic HBV infection is defined as achievement of undetectable HBV surface antigen levels and sustained suppression of HBV DNA. As previously announced in April 2021, VBI-2601 is also being assessed in an additional Phase 2 study as part of a combination regimen with BRII-835 , an investigational small interfering ribonucleic acid targeting HBV. "Our commitment to the fight against hepatitis B includes a focus on both prevention and treatment of the disease," said Jeff Baxter, VBI's President and CEO. "More than 290 million people are chronically infected with HBV worldwide and, together with our partners, we are working hard to provide more patients with improved therapeutic options. This effort includes the assessment of new investigational treatment regimens, as in the ongoing combination study of VBI-2601 and an siRNA candidate, as well as ways to potentially improve upon functional cure rates achieved with the current standard of care, as with this newly announced Phase 2 study. We believe a multi-pronged approach is critical for driving innovation in the treatment of chronic HBV, and we look forward to sharing data from these two Phase 2 studies in the second half of 2022 and the first half of 2023, respectively." Brii Biosciences is the sponsor of this newly announced Phase 2a/2b study and, with the support of VBI, has led the design and implementation of this study as well as the ongoing Phase 2 combination study.

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

12/29/21 Jefferies
VBI Vaccines assumed with a Buy at Jefferies
02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

VBIV VBI Vaccines
$2.34 /

-0.13 (-5.27%)

On The Fly
Wingstop, Akamai initiations among today's top calls on Wall Street » 09:44
12/29/21
12/29
09:44
12/29/21
09:44
WING

Wingstop

$172.71 /

+0.04 (+0.02%)

, AKAM

Akamai

$118.43 /

+0.01 (+0.01%)

, ALT

Altimmune

$8.75 /

+ (+0.00%)

, VXRT

Vaxart

$6.46 /

+ (+0.00%)

, VBIV

VBI Vaccines

$2.21 /

-0.005 (-0.23%)

, VAXX

Vaxxinity

$6.03 /

+0.02 (+0.33%)

, PCVX

Vaxcyte

$22.27 /

+0.015 (+0.07%)

, ICVX

Icosavax

$21.91 /

-0.01 (-0.05%)

, INO

Inovio

$5.34 /

+0.0001 (+0.00%)

, ABUS

Arbutus Biopharma

$3.82 /

+ (+0.00%)

, MTCR

Metracrine

/

+

, MCD

McDonald's

$267.85 /

+0.08 (+0.03%)

, NRIX

Nurix Therapeutics

$30.14 /

-0.07 (-0.23%)

Check out today's top…

ShowHide Related Items >><<
WING Wingstop
$172.71 /

+0.04 (+0.02%)

VXRT Vaxart
$6.46 /

+ (+0.00%)

VBIV VBI Vaccines
$2.21 /

-0.005 (-0.23%)

PCVX Vaxcyte
$22.27 /

+0.015 (+0.07%)

NRIX Nurix Therapeutics
$30.14 /

-0.07 (-0.23%)

MTCR Metracrine
/

+

MCD McDonald's
$267.85 /

+0.08 (+0.03%)

INO Inovio
$5.34 /

+0.0001 (+0.00%)

ICVX Icosavax
$21.91 /

-0.01 (-0.05%)

ALT Altimmune
$8.75 /

+ (+0.00%)

AKAM Akamai
$118.43 /

+0.01 (+0.01%)

ABUS Arbutus Biopharma
$3.82 /

+ (+0.00%)

WING Wingstop
$172.71 /

+0.04 (+0.02%)

12/29/21 Benchmark
Wingstop initiated with a Hold at Benchmark
12/22/21 Piper Sandler
Wingstop price target lowered to $195 from $205 at Piper Sandler
12/15/21 Barclays
Wingstop price target raised to $194 from $184 at Barclays
11/15/21 Deutsche Bank
Wingstop price target lowered to $172 from $178 at Deutsche Bank
AKAM Akamai
$118.43 /

+0.01 (+0.01%)

12/28/21 DA Davidson
DA Davidson starts Akamai at Buy on 'stable' CDN market leading position
12/28/21 DA Davidson
Akamai initiated with a Buy at DA Davidson
12/14/21 JPMorgan
Akamai downgraded to Underweight from Neutral at JPMorgan
12/14/21 JPMorgan
Akamai downgraded to Underweight from Neutral at JPMorgan
ALT Altimmune
$8.75 /

+ (+0.00%)

12/29/21 Jefferies
Altimmune assumed with a Buy at Jefferies
11/10/21 B. Riley
B. Riley keeps Buy rating on Altimmune, says 'valuation disconnect puzzling'
11/10/21 Piper Sandler
Piper says Altimmune NAFLD data for pemvidutide 'unprecedented'
10/04/21 Piper Sandler
Altimmune news provides opportunity to own shares, says Piper Sandler
VXRT Vaxart
$6.46 /

+ (+0.00%)

12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/02/21 Cantor Fitzgerald
Vaxart initiated with an Overweight at Cantor Fitzgerald
08/02/21 Piper Sandler
Piper 'pleased' to see Vaxart's IND clearance for S-only COVID vaccine candidate
VBIV VBI Vaccines
$2.21 /

-0.005 (-0.23%)

12/29/21 Jefferies
VBI Vaccines assumed with a Buy at Jefferies
02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VAXX Vaxxinity
$6.03 /

+0.02 (+0.33%)

12/29/21 Jefferies
Vaxxinity assumed with a Buy at Jefferies
12/07/21 Jefferies
Vaxxinity initiated with a Buy at Jefferies
12/06/21 BofA
Vaxxinity initiated with a Buy at BofA
12/06/21 BofA
Vaxxinity initiated with a Buy at BofA
PCVX Vaxcyte
$22.27 /

+0.015 (+0.07%)

12/29/21 Jefferies
Vaxcyte assumed with a Buy at Jefferies
06/24/21 Jefferies
Vaxcyte assumed with a Buy at Jefferies
ICVX Icosavax
$21.91 /

-0.01 (-0.05%)

12/29/21 Jefferies
Icosavax assumed with a Buy at Jefferies
08/23/21 Evercore ISI
Icosavax initiated with an Outperform at Evercore ISI
08/23/21 Cowen
Icosavax initiated with Outperform on vaccine potential at Cowen
08/23/21 William Blair
Icosavax initiated with Outperform, $45.70 fair value at William Blair
INO Inovio
$5.34 /

+0.0001 (+0.00%)

12/29/21 Jefferies
Inovio assumed with a Hold at Jefferies
09/10/21 BofA
Inovio downgraded to Underperform from Neutral at BofA
06/24/21 Jefferies
Inovio initiated with a Hold at Jefferies
05/10/21 Piper Sandler
Inovio price target lowered to $6 from $7 at Piper Sandler
ABUS Arbutus Biopharma
$3.82 /

+ (+0.00%)

12/29/21 Jefferies
Arbutus Biopharma assumed with a Hold at Jefferies
12/13/21 H.C. Wainwright
H.C. Wainwright sees Arbutus' $300M-plus licensing deal for AB-729 as low-risk
12/02/21 H.C. Wainwright
H.C. Wainwright says Arbutus patent win may mean 'considerable gain' for Roivant
12/02/21 Chardan
Arbutus Biopharma price target raised to $5.50 from $5 at Chardan
MTCR Metracrine
/

+

12/29/21 Jefferies
Metracrine assumed with a Hold at Jefferies
12/27/21 H.C. Wainwright
Metracrine CMO exit 'not a big surprise,' says H.C. Wainwright
10/22/21 Jefferies
Metracrine downgraded to Hold at Jefferies after NASH put on shelf
10/22/21 Canaccord
Metracrine downgraded to Hold with $1 target at Canaccord
MCD McDonald's
$267.85 /

+0.08 (+0.03%)

12/29/21 Tigress Financial
McDonald's price target raised to $314 from $271 at Tigress Financial
12/20/21 Edward Jones
McDonald's downgraded to Hold from Buy at Edward Jones
12/15/21 Barclays
McDonald's price target raised to $300 from $298 at Barclays
12/14/21 BTIG
McDonald's price target raised to $295 from $255 at BTIG
NRIX Nurix Therapeutics
$30.14 /

-0.07 (-0.23%)

12/29/21 H.C. Wainwright
Nurix Therapeutics initiated with a Buy at H.C. Wainwright
10/28/21 Baird
Nurix Therapeutics price target raised to $49 from $46 at Baird
10/27/21 SVB Leerink
Nurix Therapeutics price target raised to $64 from $50 at SVB Leerink
10/27/21 Piper Sandler
Nurix Phase I data 'incredibly encouraging,' says Piper Sandler
WING Wingstop
$172.71 /

+0.04 (+0.02%)

VXRT Vaxart
$6.46 /

+ (+0.00%)

VBIV VBI Vaccines
$2.21 /

-0.005 (-0.23%)

VAXX Vaxxinity
$6.03 /

+0.02 (+0.33%)

PCVX Vaxcyte
$22.27 /

+0.015 (+0.07%)

NRIX Nurix Therapeutics
$30.14 /

-0.07 (-0.23%)

MCD McDonald's
$267.85 /

+0.08 (+0.03%)

INO Inovio
$5.34 /

+0.0001 (+0.00%)

ICVX Icosavax
$21.91 /

-0.01 (-0.05%)

ALT Altimmune
$8.75 /

+ (+0.00%)

AKAM Akamai
$118.43 /

+0.01 (+0.01%)

ABUS Arbutus Biopharma
$3.82 /

+ (+0.00%)

  • 11
    Nov
  • 29
    Jul
  • 05
    Mar
  • 21
    Jan
VXRT Vaxart
$6.46 /

+ (+0.00%)

MCD McDonald's
$267.85 /

+0.08 (+0.03%)

WING Wingstop
$172.71 /

+0.04 (+0.02%)

VXRT Vaxart
$6.46 /

+ (+0.00%)

VAXX Vaxxinity
$6.03 /

+0.02 (+0.33%)

MTCR Metracrine
/

+

MCD McDonald's
$267.85 /

+0.08 (+0.03%)

INO Inovio
$5.34 /

+0.0001 (+0.00%)

ICVX Icosavax
$21.91 /

-0.01 (-0.05%)

ALT Altimmune
$8.75 /

+ (+0.00%)

AKAM Akamai
$118.43 /

+0.01 (+0.01%)

ABUS Arbutus Biopharma
$3.82 /

+ (+0.00%)

VXRT Vaxart
$6.46 /

+ (+0.00%)

VBIV VBI Vaccines
$2.21 /

-0.005 (-0.23%)

MTCR Metracrine
/

+

MCD McDonald's
$267.85 /

+0.08 (+0.03%)

INO Inovio
$5.34 /

+0.0001 (+0.00%)

ALT Altimmune
$8.75 /

+ (+0.00%)

AKAM Akamai
$118.43 /

+0.01 (+0.01%)

ABUS Arbutus Biopharma
$3.82 /

+ (+0.00%)

Initiation
VBI Vaccines assumed with a Buy at Jefferies » 05:35
12/29/21
12/29
05:35
12/29/21
05:35
VBIV

VBI Vaccines

$2.21 /

-0.105 (-4.54%)

Jefferies analyst Roger…

Jefferies analyst Roger Song assumed coverage of VBI Vaccines with a Buy rating and price target of $6, down from $7. The company has a "versatile" vaccine technology platform that represents multiple large market opportunities, Song tells investors in a research note. He views the initial PreHevbrio hepatitis B vaccine vaccine launch and COVID-19 booster data in Q1 of 2022 as :major catalysts for the stock."

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.21 /

-0.105 (-4.54%)

VBIV VBI Vaccines
$2.21 /

-0.105 (-4.54%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$2.21 /

-0.105 (-4.54%)

VBIV VBI Vaccines
$2.21 /

-0.105 (-4.54%)

Over a month ago
Hot Stocks
VBI Vaccines files NDS to Health Canada for hepatitis B vaccine candidate » 08:09
12/09/21
12/09
08:09
12/09/21
08:09
VBIV

VBI Vaccines

$2.69 /

+0.095 (+3.67%)

VBI Vaccines announced…

VBI Vaccines announced the filing of a new drug submission, or NDS, to Health Canada for the company's three-antigen prophylactic hepatitis B vaccine candidate, seeking approval in Canada for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.69 /

+0.095 (+3.67%)

VBIV VBI Vaccines
$2.69 /

+0.095 (+3.67%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$2.69 /

+0.095 (+3.67%)

VBIV VBI Vaccines
$2.69 /

+0.095 (+3.67%)

Options
Unusually active option classes on open December 1st » 09:40
12/01/21
12/01
09:40
12/01/21
09:40
ARDX

Ardelyx

$1.16 /

-0.01 (-0.85%)

, ABUS

Arbutus Biopharma

$3.20 /

+ (+0.00%)

, VBIV

VBI Vaccines

$3.04 /

+ (+0.00%)

, VTNR

Vertex Energy

$4.93 /

+ (+0.00%)

, ATNF

180 Life Sciences

$6.37 /

-0.005 (-0.08%)

, XPEV

XPeng

$55.00 /

+ (+0.00%)

, LI

Li Auto

$35.28 /

+ (+0.00%)

, AGC

Altimeter Growth

$12.80 /

+0.05 (+0.39%)

, CCJ

Cameco

$23.19 /

+ (+0.00%)

, MRK

Merck

$74.87 /

+0.01 (+0.01%)

Unusual total active…

Unusual total active option classes on open include: Ardelyx (ARDX), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Vertex Energy (VTNR), 180 Life Sciences (ATNF), XPeng (XPEV), Li Auto (LI), Altimeter Growth Corp (AGC), Cameco (CCJ), and Merck (MRK).

ShowHide Related Items >><<
XPEV XPeng
$55.00 /

+ (+0.00%)

VTNR Vertex Energy
$4.93 /

+ (+0.00%)

VBIV VBI Vaccines
$3.04 /

+ (+0.00%)

MRK Merck
$74.87 /

+0.01 (+0.01%)

LI Li Auto
$35.28 /

+ (+0.00%)

CCJ Cameco
$23.19 /

+ (+0.00%)

ATNF 180 Life Sciences
$6.37 /

-0.005 (-0.08%)

ARDX Ardelyx
$1.16 /

-0.01 (-0.85%)

AGC Altimeter Growth
$12.80 /

+0.05 (+0.39%)

ABUS Arbutus Biopharma
$3.20 /

+ (+0.00%)

ARDX Ardelyx
$1.16 /

-0.01 (-0.85%)

12/01/21 Ladenburg
Ardelyx upgraded to Buy at Ladenburg on IBS-C treatment launch plan
12/01/21 Ladenburg
Ardelyx upgraded to Buy from Neutral at Ladenburg
12/01/21 Citi
Ardelyx price target raised to $13 from $7 at Citi
11/30/21 Citi
Ardelyx price target raised to $13 from $7 at Citi
ABUS Arbutus Biopharma
$3.20 /

+ (+0.00%)

11/08/21 H.C. Wainwright
Arbutus Biopharma price target lowered to $8 from $10 at H.C. Wainwright
06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
VBIV VBI Vaccines
$3.04 /

+ (+0.00%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VTNR Vertex Energy
$4.93 /

+ (+0.00%)

12/01/21 Credit Suisse
Vertex Energy initiated with an Outperform at Credit Suisse
11/09/21 Craig-Hallum
Vertex Energy price target lowered to $18 from $25 at Craig-Hallum
06/30/21 Craig-Hallum
Vertex Energy price target raised to $25 from $13 at Craig-Hallum
06/01/21 Stifel
Vertex Energy price target raised to $17 from $2 at Stifel
ATNF 180 Life Sciences
$6.37 /

-0.005 (-0.08%)

09/15/21 Maxim
180 Life Sciences initiated with a Buy at Maxim
09/15/21 Maxim
180 Life Sciences initiated with a Buy at Maxim
XPEV XPeng
$55.00 /

+ (+0.00%)

11/24/21 BofA
XPeng price target raised to $66 from $63 at BofA
11/24/21 Citi
XPeng price target raised to $92 from $87 at Citi
11/11/21 Citi
XPeng price target raised to $87 from $53.40 at Citi
10/28/21
Fly Intel: Top five analyst initiations
LI Li Auto
$35.28 /

+ (+0.00%)

11/11/21 Citi
Li Auto price target raised to $200 from $165 at Citi
10/28/21 Bernstein
Bernstein starts Li Auto at Outperform, sees EVs as 'future' of Chinese autos
10/28/21 Bernstein
Li Auto initiated with an Outperform at Bernstein
AGC Altimeter Growth
$12.80 /

+0.05 (+0.39%)

10/01/21 New Street
Grab partner Altimeter Growth initiated with a Buy at New Street
CCJ Cameco
$23.19 /

+ (+0.00%)

11/03/21 BofA
Cameco upgraded to Buy from Neutral at BofA
11/03/21 BofA
Cameco upgraded to Buy from Neutral at BofA
11/02/21 BMO Capital
Cameco price target raised to C$28 from C$26 at BMO Capital
11/01/21 RBC Capital
Cameco price target raised to C$29 from C$26 at RBC Capital
MRK Merck
$74.87 /

+0.01 (+0.01%)

11/29/21
Fly Intel: Top five analyst downgrades
11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 Citi
Merck downgraded to Neutral from Buy at Citi
XPEV XPeng
$55.00 /

+ (+0.00%)

VTNR Vertex Energy
$4.93 /

+ (+0.00%)

VBIV VBI Vaccines
$3.04 /

+ (+0.00%)

MRK Merck
$74.87 /

+0.01 (+0.01%)

LI Li Auto
$35.28 /

+ (+0.00%)

CCJ Cameco
$23.19 /

+ (+0.00%)

ARDX Ardelyx
$1.16 /

-0.01 (-0.85%)

ABUS Arbutus Biopharma
$3.20 /

+ (+0.00%)

  • 13
    Aug
  • 09
    Dec
  • 04
    Dec
XPEV XPeng
$55.00 /

+ (+0.00%)

MRK Merck
$74.87 /

+0.01 (+0.01%)

AGC Altimeter Growth
$12.80 /

+0.05 (+0.39%)

XPEV XPeng
$55.00 /

+ (+0.00%)

VTNR Vertex Energy
$4.93 /

+ (+0.00%)

MRK Merck
$74.87 /

+0.01 (+0.01%)

LI Li Auto
$35.28 /

+ (+0.00%)

ARDX Ardelyx
$1.16 /

-0.01 (-0.85%)

AGC Altimeter Growth
$12.80 /

+0.05 (+0.39%)

ABUS Arbutus Biopharma
$3.20 /

+ (+0.00%)

XPEV XPeng
$55.00 /

+ (+0.00%)

VTNR Vertex Energy
$4.93 /

+ (+0.00%)

MRK Merck
$74.87 /

+0.01 (+0.01%)

LI Li Auto
$35.28 /

+ (+0.00%)

CCJ Cameco
$23.19 /

+ (+0.00%)

ATNF 180 Life Sciences
$6.37 /

-0.005 (-0.08%)

ARDX Ardelyx
$1.16 /

-0.01 (-0.85%)

AGC Altimeter Growth
$12.80 /

+0.05 (+0.39%)

ABUS Arbutus Biopharma
$3.20 /

+ (+0.00%)

Hot Stocks
VBI Vaccines announces FDA approval of PreHevbrio » 07:36
12/01/21
12/01
07:36
12/01/21
07:36
VBIV

VBI Vaccines

$3.04 /

+0.205 (+7.23%)

VBI Vaccines announced…

VBI Vaccines announced that the FDA has approved PreHevbrio for the prevention of infection caused by all known subtypes of hepatitis B virus, or HBV, in adults age 18 years and older. PreHevbrio contains the S, pre-S2, and pre-S1 HBV surface antigens, and is the only approved 3-antigen HBV vaccine for adults in the U.S.

ShowHide Related Items >><<
VBIV VBI Vaccines
$3.04 /

+0.205 (+7.23%)

VBIV VBI Vaccines
$3.04 /

+0.205 (+7.23%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$3.04 /

+0.205 (+7.23%)

Conference/Events
FDA PDUFA Date for VBI Vaccines 3-Antigen Prophylactic Hepatitis B Vaccine » 04:55
11/30/21
11/30
04:55
11/30/21
04:55
VBIV

VBI Vaccines

$2.84 /

+0.05 (+1.79%)

The PDUFA Date is…

The PDUFA Date is November 30, 2021.

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.84 /

+0.05 (+1.79%)

VBIV VBI Vaccines
$2.84 /

+0.05 (+1.79%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$2.84 /

+0.05 (+1.79%)

Conference/Events
FDA PDUFA Date for VBI Vaccines 3-Antigen Prophylactic Hepatitis B Vaccine » 22:34
11/29/21
11/29
22:34
11/29/21
22:34
VBIV

VBI Vaccines

$2.84 /

+0.05 (+1.79%)

The PDUFA Date is…

The PDUFA Date is November 30, 2021.

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.84 /

+0.05 (+1.79%)

VBIV VBI Vaccines
$2.84 /

+0.05 (+1.79%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$2.84 /

+0.05 (+1.79%)

Earnings
VBI Vaccines reports Q3 EPS (7c), consensus (6c) » 08:05
11/08/21
11/08
08:05
11/08/21
08:05
VBIV

VBI Vaccines

$2.99 /

-0.13 (-4.17%)

Reports Q3 revenue…

Reports Q3 revenue $107,000, consensus $200,000. Jeff Baxter, VBI's president and CEO commented: "The third quarter of 2021 was a notably busy and productive time as we support the ongoing regulatory reviews of our prophylactic 3-antigen HBV vaccine candidate, prepare for the potential launch of this candidate in the U.S., Europe, and Canada, and advance both our immunotherapeutic vaccine candidates against GBM and chronic HBV, as well as our coronavirus pipeline, with the objective of creating vaccines that provide long-term breadth of protection with good safety and tolerability profiles. We look forward to sharing data and updates from the various milestones expected over the next six months across our portfolio. The public health space is constantly evolving, evidenced by the renewed focus on prevention of HBV with the recently revised adult vaccination guidelines, plus the mutational evolution of COVID-19 with new and emerging variants. We are working hard to address significant and relevant unmet medical and public health needs, we believe this dedication and focus on successfully achieving these fundamentals will drive shareholder value."

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.99 /

-0.13 (-4.17%)

VBIV VBI Vaccines
$2.99 /

-0.13 (-4.17%)

02/25/21 Jefferies
VBI Vaccines initiated with a Buy at Jefferies
VBIV VBI Vaccines
$2.99 /

-0.13 (-4.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.